Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHelios Towers Regulatory News (HTWS)

Share Price Information for Helios Towers (HTWS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 124.60
Bid: 124.80
Ask: 125.40
Change: 0.60 (0.48%)
Spread: 0.60 (0.481%)
Open: 126.20
High: 126.80
Low: 123.00
Prev. Close: 124.60
HTWS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Conditional Redemption of Senior Notes

20 May 2024 08:15

RNS Number : 0664P
Helios Towers PLC
20 May 2024
 

This announcement contains inside information for the purpose of Article 7 of the Market Abuse Regulation (EU) 596/2014

NOT FOR DISTRIBUTION IN OR INTO ANY JURISDICTION OR TO ANY PERSON LOCATED OR RESIDENT IN ANY JURISDICTION IN WHICH SUCH DISTRIBUTION IS UNLAWFUL

 

HELIOS TOWERS ANNOUNCES CONDITIONAL NOTICE OF REDEMPTION FOR ALL OF ITS OUTSTANDING 7.000% SENIOR NOTES DUE 2025

May 20, 2024 - HTA Group, Ltd (the "Issuer"), an indirect wholly owned subsidiary of Helios Towers plc (the "Company"), announces it has issued a conditional notice of redemption for all of its outstanding 7.000% Senior Notes due 2025 (the "Notes"). As set forth in the conditional notice of redemption issued today in respect of the Notes, the redemption date is June 18, 2024 (the "Redemption Date") unless the Redemption Date is delayed or revoked by the Issuer, and the redemption price for the Notes is 100.000% of the principal amount thereof, plus the amount of accrued and unpaid interest to, but excluding, the Redemption Date.

On the date hereof, the Issuer also announced (i) its offer to purchase for cash any and all of the Notes (the "Tender Offer") and (ii) an offering of new U.S. dollar-denominated senior notes subject to market conditions (the "New Notes Offering"). Any notes issued pursuant to the New Notes Offering and the guarantees in respect thereof have not been and will not be registered under the United States Securities Act of 1933. Neither the Tender Offer nor this announcement is an offer to sell or a solicitation of an offer to buy any notes issued pursuant to the New Notes Offering. No action has been or will be taken in any jurisdiction in relation to any notes issued pursuant to the New Notes Offering to permit a public offering of securities. This notice does not constitute an offer to sell, or a solicitation of an offer to buy, any security. No offer, solicitation, or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful.

The redemption is subject to and conditioned upon the successful completion (in the sole determination of the Issuer) of the New Notes Offering.

Forward-Looking Information

Certain statements included herein may constitute forward-looking statements within the meaning of the securities laws of certain jurisdictions. Certain such forward-looking statements can be identified by the use of forward-looking terminology such as "believes", "expects", "may", "are expected to", "intends", "will", "will continue", "should", "would be", "seeks", "anticipates" or similar expressions or the negative thereof or other variations thereof or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of the Issuer concerning, among other things, the results in relation to operations, financial condition, liquidity, prospects, growth and strategies of the Issuer and the industry in which it operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future.

These forward-looking statements speak only as of the date of this announcement. The Issuer does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCQBLBLZELXBBE
Date   Source Headline
31st May 20244:35 pmRNSTender Results Announcement
23rd May 20247:00 amRNSBond Refinancing
20th May 20248:15 amRNSConditional Redemption of Senior Notes
20th May 20248:14 amRNSLaunch of Senior Notes
20th May 20248:14 amRNSOffer to Purchase 2025 Notes
16th May 20247:00 amRNSQ1 2024 Results
10th May 20247:00 amRNSDirectorate Change
3rd May 20247:00 amRNSBlock Listing Six Monthly Return
2nd May 20243:41 pmRNSDirector/PDMR Shareholding
25th Apr 20243:40 pmRNS2024 Annual General Meeting Results
23rd Apr 20247:00 amRNSNotice of Q1 2024 Results Date & Conference Call
22nd Apr 20247:00 amRNSCredit rating upgrade
16th Apr 20242:29 pmRNSDirector/PDMR Shareholding
28th Mar 20248:57 amRNSTotal Voting Rights
25th Mar 202410:31 amRNSDoc re Annual Report and Financial Statements
20th Mar 202412:31 pmRNSDirector/PDMR Shareholding
19th Mar 20242:52 pmRNSHolding(s) in Company
19th Mar 20247:56 amRNSHolding(s) in Company
15th Mar 202412:52 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSResults for the year and quarter ended 31 Dec 2023
26th Jan 20249:00 amRNSDirectorate Change
18th Jan 20247:00 amRNSNotice of FY 2023 Results Date & Conference Call
3rd Nov 20237:05 amRNSBlock Listing Interim Review
2nd Nov 20237:00 amRNSQ3 2023 Results
16th Oct 20237:01 amRNSResults of capped tender offer
16th Oct 20237:00 amRNSResults of Tender Offer for Senior Notes
10th Oct 20237:00 amRNSNotice of Q3 2023 Results Date & Conference Call
3rd Oct 20231:29 pmRNSDirector/PDMR Shareholding
28th Sep 20231:34 pmRNSExtension of Early Tender Time
14th Sep 20237:05 amRNSNew Facilities and tender offer of Senior Notes
14th Sep 20237:00 amRNSUp to $400m Tender Offer for Senior Notes
3rd Aug 20237:00 amRNSHalf-year Report
4th Jul 20237:00 amRNSNotice of H1 2023 Results Date & Conference Call
23rd May 20231:39 pmRNSDirector/PDMR Shareholding
18th May 20232:00 pmRNSDirector/PDMR Shareholding
18th May 20232:00 pmRNSDirectorate Change
18th May 20237:00 amRNSQ1 2023 Results
3rd May 202311:25 amRNSBlock Listing Interim Review
27th Apr 20233:39 pmRNS2023 Annual General Meeting Results
17th Apr 20239:44 amRNSNotice of Q1 2023 Results Date & Conference Call
27th Mar 20232:16 pmRNS2022 Annual Report and 2023 Notice of AGM
16th Mar 20237:00 amRNSFinal Results
27th Jan 20237:00 amRNSNotice of FY2022 Results Date & Conference Call
15th Dec 20225:56 pmRNSHolding in Company
8th Dec 20222:55 pmRNSClosing of tower acquisition in Oman
30th Nov 20227:00 amRNSTotal Voting Rights
25th Nov 20227:00 amRNSUpdate on Omantel Tower Portfolio Acquisition
14th Nov 20227:00 amRNSOmantel Tower Acquisition Long-Stop Date Extension
9th Nov 20228:53 amRNSHolding(s) in Company
3rd Nov 20227:00 amRNSQ3 2022 Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.